NRX PharmaceuticalsNRXP
13F holders, Q2 2026 (June 30)At the end of Q2 2026, 47 institutions reported holding NRX Pharmaceuticals Inc. (NRXP) in their 13F filings, up 14 from Q1 2026. 18 opened new positions and 5 sold out. The largest holders were B Group, Inc. ($16.7M), Vanguard Capital Management LLC ($6.6M) and Ameriprise Financial Inc. ($3.8M). 3 famous investors held it, including Ken Griffin (0.0% of Citadel Advisors's portfolio), Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- NRX Pharmaceuticals Inc.
- CUSIP
- 629444209
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 18 | $12.3M |
| Exits | 5 | $201K |
All 13F filers, Q1 2026 → Q2 2026: 5,570,884 shares bought and 170,571 shares sold, net +5,400,313 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 47 holders
| B Group, Inc. | 9.50% | Add +36.4% | 4,091,767 | $16.7M |
| Vanguard Capital Management LLC | 0.00% | Add +39.5% | 1,618,159 | $6.6M |
| Ameriprise Financial Inc. | 0.00% | New | 928,728 | $3.8M |
| Balyasny Asset Management L.P. | 0.01% | New | 893,864 | $3.7M |
| Citadel Advisors | 0.00% | New | 680,043 | $2.8M |
| AdvisorShares Investments LLC | 0.33% | Add +56.7% | 659,018 | $2.7M |
| Commonwealth Equity Services, LLC | 0.00% | Add +14.3% | 454,418 | $1.9M |
| UBS Group AG | 0.00% | Add +1577.2% | 423,115 | $1.7M |
| Geode Capital Management, LLC | 0.00% | Add +1.5% | 314,659 | $1.3M |
| BlackRock, Inc. | 0.00% | Add +122.7% | 220,460 | $902K |
| Marshall Wace, LLP | 0.00% | New | 194,580 | $796K |
| Vanguard Fiduciary Trust Co. | 0.00% | Add +7.8% | 182,718 | $747K |
| Jane Street Group, LLC | 0.00% | Add +169.6% | 119,018 | $487K |
| Bleakley Financial Group, LLC | 0.01% | Add +0.0% | 117,216 | $479K |
| State Street Corp. | 0.00% | Add +33.5% | 116,084 | $475K |
| HRT Financial LP | 0.00% | New | 100,724 | $411K |
| Northern Trust Corp. | 0.00% | Add +44.8% | 62,951 | $257K |
| Chicago Partners Investment Group LLC | 0.00% | Add +34.5% | 46,388 | $191K |
| Quadrature Capital Ltd | 0.00% | New | 43,605 | $178K |
| One Wealth Management Investment & Advisory Services, LLC | 0.19% | No change | 43,309 | $177K |
| Morgan Stanley | 0.00% | Add +307.9% | 40,901 | $167K |
| Renaissance Technologies | 0.00% | New | 38,600 | $158K |
| Global Retirement Partners, LLC | 0.00% | — | 33,300 | $136K |
| Two Sigma Investments, LP | 0.00% | New | 26,429 | $108K |
| Truist Financial Corp. | 0.00% | New | 20,000 | $82K |
| ExodusPoint Capital Management, LP | 0.00% | New | 19,308 | $79K |
| XTX Topco Ltd | 0.00% | Reduce -76.5% | 18,545 | $76K |
| Virtu Financial LLC | 0.00% | Reduce -47.7% | 16,614 | $68K |
| Persistent Asset Partners Ltd | 0.02% | New | 16,326 | $67K |
| Cresset Asset Management, LLC | 0.00% | New | 15,000 | $61K |
| Sjbenen Advisory, LLC | 0.03% | No change | 15,000 | $58K |
| Squarepoint Ops LLC | 0.00% | New | 13,166 | $54K |
| Ethos Financial Group, LLC | 0.00% | No change | 15,900 | $51K |
| Millennium Management | 0.00% | New | 12,305 | $50K |
| Citigroup Inc. | 0.00% | New | 5,992 | $25K |
| Vanguard Global Advisers, LLC | 0.00% | New | 5,773 | $24K |
| SBI Securities Co., Ltd. | 0.00% | Add +104.0% | 5,101 | $21K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +4695.1% | 3,884 | $16K |
| Wells Fargo & Company | 0.00% | Reduce -14.9% | 2,000 | $8K |
| Royal Bank of Canada | 0.00% | Reduce -20.3% | 2,000 | $8K |
| Barclays PLC | 0.00% | New | 900 | $4K |
| Osaic Holdings, Inc. | 0.00% | Add +566.7% | 600 | $2K |
| Avion Wealth | 0.00% | No change | 294 | $1K |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 67 | $274 |
| JPMorgan Chase & Co. | 0.00% | No change | 34 | $136 |
| Larson Financial Group LLC | 0.00% | No change | 22 | $90 |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 1 | $4 |
"% of holder's portfolio" is NRXP's weight in each manager's 13F, not the share of NRX Pharmaceuticals Inc. the manager owns.